domingo, 20 de setembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 5, 2026

Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering

View original at finance.yahoo.com
Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering Dataset grows to more than 312,000 whole genomes with longitudinal clinical data GSK is one of the first to lead a further expansion of 50,000 whole genomes paired with proteomic data SAN DIEGO, March 5, 20…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Vanderbilt has an exceptional biobank and population-scale genetics program — one of the most impressive in the world

    80% confidence
  • Human genetics is the most powerful compass we have for finding the right targets and delivering the best innovative medicines

    80% confidence
  • The AGD dataset is among the largest collections of whole genome sequences available, and it is the world's largest pairing of whole genome sequences with the depth of clinical data that comes from a leading academic medical center

    80% confidence
  • There is proven value in the integration of proteomics and comprehensive datasets, evidenced by the boon of large-scale studies showing promise in pinpointing drug targets linked to human disease

    80% confidence
  • AGD has already enabled disease-impacting discoveries in autoimmune disease and obesity, with many more such studies underway, and continued expansion accelerates this progress

    80% confidence
  • Integrating high-quality clinical and genomic data with advanced AI will help pharma translate discoveries into meaningful advances for patients

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
Sinalizamos conflitos abertamente ›
Verificado recentemente
Verificado com a fonte original
4,982
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,982 factos verificados com a fonte5,299 documentos-fonte arquivados
Consulte estes dados → isubstrate.com